Jennifer Chao Joins Leerink Swann & Company as Vice President-Senior Analyst, Biotechnology

Apr 27, 2001, 01:00 ET from Leerink Swann & Company

    BOSTON, April 27 /PRNewswire/ -- Jennifer Chao has joined Leerink Swann &
 Company as Vice President-Senior Analyst, Biotechnology. Ms. Chao joins us
 from Deutsche Banc Alex. Brown and UBS Paine Webber, Inc. where she was an
 Associate Analyst. As a recipient of a Harvard Medical School Biomedical
 Research Careers Award, she completed a Fellowship in Neurogenetics at Harvard
 Medical School and Massachusetts General Hospital. With Leerink Swann &
 Company Ms. Chao will continue her focus on mid to large cap biotechnology
 companies.
 
     About Leerink Swann & Company
     Leerink Swann & Company, recently ranked 30th on the Inc. 500 list of the
 country's fastest growing companies, is a full-service investment banking firm
 that provides healthcare equity research, corporate finance, asset management
 services for high net worth clients, and institutional sales. Through its
 subsidiary MEDACorp, Leerink Swann & Company provides biomedical-consulting
 services to Life Science companies and to the institutional investment
 community. MEDACorp is comprised of more than 2,000 consultants who are
 practicing physicians, surgeons, and biomedical professionals representing 48
 clinical care specialties and 22 basic science disciplines.
     For information on Leerink Swann & Company's coverage of the biotechnology
 sector, please contact Ms. Chao at (617) 918-4537. For more information on
 this press release, contact Katie Gilbert (617) 918-4528.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X66631117
 
 

SOURCE Leerink Swann & Company
    BOSTON, April 27 /PRNewswire/ -- Jennifer Chao has joined Leerink Swann &
 Company as Vice President-Senior Analyst, Biotechnology. Ms. Chao joins us
 from Deutsche Banc Alex. Brown and UBS Paine Webber, Inc. where she was an
 Associate Analyst. As a recipient of a Harvard Medical School Biomedical
 Research Careers Award, she completed a Fellowship in Neurogenetics at Harvard
 Medical School and Massachusetts General Hospital. With Leerink Swann &
 Company Ms. Chao will continue her focus on mid to large cap biotechnology
 companies.
 
     About Leerink Swann & Company
     Leerink Swann & Company, recently ranked 30th on the Inc. 500 list of the
 country's fastest growing companies, is a full-service investment banking firm
 that provides healthcare equity research, corporate finance, asset management
 services for high net worth clients, and institutional sales. Through its
 subsidiary MEDACorp, Leerink Swann & Company provides biomedical-consulting
 services to Life Science companies and to the institutional investment
 community. MEDACorp is comprised of more than 2,000 consultants who are
 practicing physicians, surgeons, and biomedical professionals representing 48
 clinical care specialties and 22 basic science disciplines.
     For information on Leerink Swann & Company's coverage of the biotechnology
 sector, please contact Ms. Chao at (617) 918-4537. For more information on
 this press release, contact Katie Gilbert (617) 918-4528.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X66631117
 
 SOURCE  Leerink Swann & Company